Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma, Inc. (symbol: TBPH) is the issuer of record for a Form 4 filing submitted to the SEC.
Theravance Biopharma, Inc. (TBPH) ownership amendment reports zero beneficial ownership for Weiss Asset Management, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, each at 0.0% of the class. It states that BIP and BGO each held zero shares, and that the reporting persons did not effect transactions in the issuer’s shares during the past 60 days.
The percentages were calculated using the issuer’s 51,918,754 shares issued and outstanding as of July 31, 2026. The statement says the issuer’s shares were cancelled on September 23, 2026, in connection with completion of its merger with Zymeworks Inc. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interests.
Theravance Biopharma, Inc. (symbol: TBPH) is the issuer of record for a Form 4 filing submitted to the SEC. PAKIANATHAN DEEPIKA reported disposition transactions in this Form 4 filing.
Theravance Biopharma, Inc. became a wholly owned subsidiary of Zymeworks Inc. on September 23, 2026; director Deepika Pakianathan’s 58,065 ordinary shares were canceled for $17.00 cash per share and one contingent value right (CVR) per share.
At the merger’s effective time, 6,009 shares underlying her RSU awards were converted into cash calculated using the $17.00 per-share consideration, subject to required tax withholdings, plus one CVR per underlying share. Seven reported option tranches were canceled: options with exercise prices below $17.00 were converted into cash based on the excess of $17.00 over the exercise price, multiplied by underlying shares, plus one CVR per underlying share; options priced at or above $17.00 were canceled without consideration.
Theravance Biopharma, Inc. director Donal O'Connor reported that 74,204 ordinary shares were canceled in the September 23, 2026 merger with Zymeworks Inc., converting into the right to receive $17.00 in cash and one contingent value right (CVR) per share. A further 6,009 shares underlying RSU awards converted into the right to receive cash based on $17.00 per share, subject to required tax withholding, plus one CVR per share. His share options were canceled: options with exercise prices below $17.00 converted into cash based on the excess over the exercise price, plus CVRs; options priced at or above $17.00 ceased to exist without consideration.
Theravance Biopharma, Inc. (symbol: TBPH) is the issuer of record for a Form 4 filing submitted to the SEC. MITCHELL DEAN J reported disposition transactions in this Form 4 filing.
Theravance Biopharma, Inc. (TBPH) director Dean J. Mitchell’s 91,204 ordinary shares were cancelled at the merger’s effective time on September 23, 2026, and converted into $17.00 cash per share plus one contingent value right (CVR) per share. His 6,009 shares underlying restricted stock unit awards were converted under the same cash and CVR terms, subject to required tax withholdings. Options were cancelled; those with exercise prices below $17.00 were converted into cash based on the excess of $17.00 over the exercise price, plus one CVR per underlying share. Options with exercise prices at or above $17.00 ceased without consideration. CVRs are non-tradeable and provide for cash payments based on commercial milestones following the merger’s effective time.
Theravance Biopharma, Inc. director Susannah Gray reported dispositions of ordinary shares and equity awards on September 23, 2026, when the company became a wholly owned subsidiary of Zymeworks Inc. Under the merger terms, her 42,137 ordinary shares were canceled and converted into the right to receive $17.00 cash per share, without interest, plus one non-tradeable contingent value right (CVR) per share. Each CVR is a contractual contingent right to cash payments based on achievement of certain commercial milestones following the merger’s effective time.
Her 6,009 restricted stock units were converted into cash based on $17.00 per underlying share, subject to required tax withholding, plus one CVR per underlying share. Five option awards were canceled and converted into rights to cash equal to any excess of $17.00 over each exercise price, multiplied by underlying shares, plus one CVR per share: 32,666 at $9.87; 22,044 at $10.95; 23,576 at $9.49; 24,258 at $9.39; and 13,398 at $16.64.
Theravance Biopharma, Inc. became a wholly owned subsidiary of Zymeworks Inc. on September 23, 2026; director Laurie Smaldone Alsup reported the resulting disposition of her securities at the merger’s effective time.
Her 74,980 ordinary shares converted into the right to receive $17.00 in cash per share, without interest, plus one contingent value right (CVR) per share. The 6,009 shares underlying her restricted stock unit award converted into cash based on the same per-share amount, subject to required tax withholding, plus one CVR per underlying share. Her options were canceled; those with exercise prices below $17.00 converted into cash for the excess, if any, over the exercise price, plus one CVR per underlying share, while options priced at or above $17.00 were canceled without consideration.
Theravance Biopharma, Inc. (symbol: TBPH) is the issuer of record for a Form 4 filing submitted to the SEC. Winningham Rick E reported disposition transactions in this Form 4 filing.
Theravance Biopharma, Inc. became a wholly owned subsidiary of Zymeworks Inc. on September 23, 2026. CEO and director Rick E. Winningham reported cancellation of 1,382,272 directly held ordinary shares, 23,400 held as custodian and 92,567 by trust; each share converted into $17.00 cash and one contingent value right. The merger also cancelled and converted 515,000 options with a $10.24 exercise price into rights to cash equal to any excess of $17.00 over the exercise price, multiplied by the underlying shares, plus one CVR per underlying share. The 151,875 restricted stock unit awards and 76,875 performance restricted stock unit awards became rights to cash based on $17.00 per underlying share plus one CVR per underlying share.
Theravance Biopharma, Inc. SVP and Chief Financial Officer Sawaf Aziz reported the disposition to the issuer of 204,966 ordinary shares on September 23, 2026. In the merger, each share he held was cancelled for the right to receive $17.00 in cash, without interest, plus one non-tradeable contingent value right (CVR) tied to commercial milestones.
On the same date, 108,436 ordinary shares underlying his restricted stock unit awards and 23,439 underlying his performance restricted stock unit awards were cancelled and converted into a right to receive cash based on $17.00 per underlying share, plus one CVR per share. The performance-award amount was based on shares that remained outstanding and unreleased immediately before the merger's effective time. Theravance became a wholly owned subsidiary of Zymeworks Inc. at the effective time. No Rule 10b5-1 plan is reported.